Breast Cancer | Specialty

Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer

June 2nd 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Ribociclib Benefit in Breast Cancer Sustained With Longer Follow-Up

June 2nd 2017

Frontline treatment with ribociclib plus letrozole improved progression-free survival by 9.3 months compared with letrozole plus placebo for patients with postmenopausal HR-positive, HER2-negative advanced breast cancer.

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

June 2nd 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

Dr. Piccart on Personalized Care for Breast Cancer

May 31st 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.

Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

May 31st 2017

Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer

May 31st 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer.

Dr. Cardoso on the Global mBC Vision 2025 Call-to-Action

May 30th 2017

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Champalimaud Clinical Cancer Center, discusses the Global mBC Vision 2025 Call-to-Action.

ASCO 2017: Oncology Leaders Pick Their Top Abstracts

May 30th 2017

Key opinion leaders spoke with OncLive to share the top-5 abstracts they find to be the most exciting and/or potentially practice-changing across breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, hematologic malignancies, and supportive care being presented at the 2017 ASCO Annual Meeting.

Breast Cancer Guidelines Outlook Covers Radiotherapy, Biomarkers, and More

May 29th 2017

Updated guidelines for the management of invasive breast cancer, issued by the National Comprehensive Cancer Network, define indications for radiation therapy, the use of biomarkers and multigene assays in clinical decision making, and new concepts in endocrine therapy in early-stage and advanced-stage estrogen receptor-positive breast cancer.

Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast Cancer

May 28th 2017

Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

TNBC Remains Challenging Arena, But Emerging Therapies Show Promise

May 25th 2017

Kari B. Wisinski, MD, discusses the evolving but challenging field of TNBC and what therapies are moving through the pipeline in TNBC and other breast cancer subtypes.

FDA Panel Supports Neratinib Approval for HER2+ Breast Cancer

May 24th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 12-4 recommending approval of neratinib (Nerlynx) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Further Advances in Breast Cancer Genomics Needed to Optimize Treatment

May 23rd 2017

Mark Burkard, MD, PhD, discusses the steps researchers are taking to address questions on genomics in breast cancer and what subtypes pose the greatest challenges.

Weaving Through the Landscape of HER2-Positive Breast Cancer

May 23rd 2017

Adam M. Brufsky, MD, PhD, discusses neratinib, overcoming resistance to HER2-targeted therapy, and the impact of newer agents in HER2-positive breast cancer.

Pyrotinib Shows Early Promise in HER2+ Breast Cancer

May 23rd 2017

In phase I results from China published in the Journal of Clinical Oncology, oral pyrotinib (HTI-1001) was well-tolerated and showed antitumor activity in women with HER2-positive breast cancer.

Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies

May 23rd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses resistance to HER2-targeted therapy in breast cancer.

Expert Explains Individualized Decision on Endocrine Therapy Beyond 5 Years in Breast Cancer

May 22nd 2017

Amye J. Tevaarwerk, MD, discusses how physicians decide on extending endocrine therapy beyond 5 years for patients with ER-positive breast cancer, the tools she hopes will soon become available to help clarify this decision, and the clinical research in this population she is eagerly awaiting.

Using Ribociclib in the First-Line Setting

May 22nd 2017

First-Line Patient Selection for CDK Inhibitor Use

May 22nd 2017

Recent FDA Approval of Ribociclib as Upfront Therapy

May 22nd 2017